A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Active, not recruiting · Phase 1, Phase 2 · NCT06833008
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $315,201
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 42
About the trial
- Sponsor
- Ipsen
- Tested
- IPN01195 (drug)
- Dates
- Started 2025-03-14; completion 2028-04-04
- Results posted
- Not yet
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.
From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Pharma Sas reported $315,201 in research payments for this study in 2025 (112 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Manish Sharma, M.D. Medical Oncology · Grand Rapids, MI
- Meredith A. Mckean, M.D. Hematology & Oncology · Nashville, TN
- Minal A. Barve, M.D. Medical Oncology · Dallas, TX
- Douglas W. Orr, MD Medical Oncology · Dallas, TX
- William B. Mckean JR., M.D., PH.D. Student in an Organized Health Care Education/Training Program · Salt Lake City, UT
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Granger Medical Clinic $140,088
- Sarah Cannon Research Institute $118,010
- Cancer and Hematology Centers of Western Michigan, PC $50,696
- Next Oncology $5,196
- Mary Crowley Cancer Research $1,081
- Next Oncology Virginia $130
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.